A stem cell knee injection may use prepared marrow or fat, and relief isn't certain

Less soreness does not prove the joint was repaired

A same-day cell procedure starts with bone marrow drawn from your pelvis or a small amount of body fat, which the clinic processes before placing the concentrated marrow liquid or fat-based liquid into your sore joint that day. These liquids contain many kinds of cells, and the share that can change into other cell types is small and uneven.

Research hasn't shown that this marrow or fat procedure delays replacement. It also hasn't shown steady repair of worn cartilage, the smooth covering on the ends of your bones. That doesn't mean nobody feels better. Still, no one knows how much comes from the procedure or how long relief will last.

That uncertainty matters when you're paying the bill.

QC Kinetix tells you what its procedure contains

QC Kinetix uses the term biologic therapies for non-surgical care made from blood components drawn from you. Its regenerative treatments are clinic procedures. The medical providers examine you, perform the procedure, and discuss what follows. PRP may be one choice. It's your blood spun so the plasma, its liquid part, carries more platelets, small blood parts that gather at a cut.

Ask which blood component the clinic plans to draw and how the clinic prepares it. Find out who will put it into your joint. Get the full price and follow-up instructions before you decide. If the answer hides behind a broad medical name, ask again.

Plain words protect your wallet here.

The visit should cover every sensible choice

The talk shouldn't begin and end with a clinic procedure. Exercise, pacing, a brace, a cane, and medicine may still help. Surgery may make more sense when wear is severe. Your health and current medicines matter as well.

Point to the sore spot, then tell the provider how long it has hurt and which motions cause more soreness. Bring an X-ray if you have one. Say what you want to do again, whether that's walking farther or sleeping through the night.

You may hear yes, no, or not yet.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A 2024 systematic review of 8 Level I randomized trials in 937 patients found bone marrow aspirate concentrate improved pain and function versus baseline from one month, but the comparative advantage over other injections was inconsistent across timepoints.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

3. A Bayesian network meta-analysis of 48 randomized trials covering 9,338 knees found hyaluronic acid and PRP significantly improved pain versus placebo, and that BMAC accounted for only 2.5 percent of the studied injections - the thinnest evidence base of the four comparators.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

4. A 2025 randomized trial of 66 knee osteoarthritis patients compared a single adipose stromal vascular fraction injection, conventional rehabilitation alone, and the two combined over 12 months - a design that treats exercise-based rehabilitation as a genuine comparator rather than an afterthought.

   Lu J, et al. — Intraarticular injection of the stromal vascular fraction for the treatment of knee osteoarthritis a prospective randomized controlled clinical trial. Sci Rep, 2025. DOI: 10.1038/s41598-025-09398-w.

5. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

6. A meta-analysis of 14 placebo cohorts across 13 Level I trials in 1,076 knee osteoarthritis patients found that intra-articular saline - the placebo - produced pain and function improvements exceeding the minimal clinically important difference at 3 and 6 months.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. Am J Sports Med, 2017. DOI: 10.1177/0363546516680607.

7. A double-blind randomized trial testing whether adding bone marrow aspirate concentrate to arthroscopic partial meniscectomy improves outcomes in patients with early knee osteoarthritis used the IKDC score at one year as its primary endpoint, with Kellgren-Lawrence grade as a radiographic secondary.

   Yanke AB, et al. — A Prospective, Randomized, Double-Blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate During Arthroscopic Meniscectomy in Patients With Early Knee Osteoarthritis. Am J Sports Med, 2024. DOI: 10.1177/03635465241275647.

8. A 2024 systematic review of bone marrow aspirate concentrate for HIP osteoarthritis found the clinical evidence base thinner than for the knee, with most studies uncontrolled - the joint matters, and evidence does not transfer across joints.

   Chandrashekar S, et al. — Safety and Efficacy of Bone-Marrow Aspirate Concentrate in Hip Osteoarthritis: A Systematic Review of Current Clinical Evidence. Indian J Orthop, 2024. DOI: 10.1007/s43465-024-01183-7.

9. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.